Close Menu

Losing Its Luster

Derek Lowe doesn't think RNAi will ever be useful in drug therapies, mainly because "nucleic acid-based therapies are just nightmarish to administer," he says. And he's not the only one. In a post at In the Pipeline, Lowe links to a recent CNBC story that details Leerink Swann's coverage of Alnylam.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.